Non-Alcoholic Fatty Liver Disease in HIV Infection

被引:0
|
作者
Macias, Juan [1 ]
Pineda, Juan A. [1 ]
Real, Luis M. [1 ]
机构
[1] Hosp Univ Valme, Infect Dis & Microbiol Unit, Avda Bellavista S-N, Seville 41014, Spain
关键词
Antiretroviral therapy; HCV infection; HIV infection; NAFLD; Steatohepatitis; HEPATITIS-C-VIRUS; CONTROLLED ATTENUATION PARAMETER; HCV COINFECTED PATIENTS; TRANSIENT ELASTOGRAPHY; RISK-FACTORS; MITOCHONDRIAL TOXICITY; CONFERS SUSCEPTIBILITY; NONINVASIVE DIAGNOSIS; MONOINFECTED PATIENTS; FIBROSIS PROGRESSION;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Non-alcoholic fatty liver disease is one of the most frequent chronic hepatic conditions worldwide. The spectrum of non-alcoholic fatty liver disease goes from hepatic steatosis to steatohepatitis, cirrhosis, and hepatocellular carcinoma. Risk factors for non-alcoholic fatty liver disease are metabolic, mainly obesity and the accompanying consequences. Treatment and prevention of non-alcoholic fatty liver disease should target those metabolic abnormalities. The frequency of and the factors associated with hepatic steatosis in HIV infection seem to be similar to those reported in the general population, though direct comparisons are lacking. Hepatic steatosis in HIV infection may also be secondary to antiretroviral drugs or HCV-related factors in HCV-coinfected subjects. However, more recent data suggest that hepatic steatosis in HIV infection represents true non-alcoholic fatty liver disease. As such, management of non-alcoholic fatty liver disease in HIV infection should follow the same principles as in the general population.
引用
收藏
页码:35 / 46
页数:12
相关论文
共 50 条
  • [41] Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Stavropoulos, Konstantinos
    Imprialos, Konstantinos
    Pittaras, Andreas
    Faselis, Charles
    Narayan, Puneet
    Kokkinos, Peter
    CURRENT VASCULAR PHARMACOLOGY, 2018, 16 (03) : 239 - 245
  • [42] PTEN in Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis and Cancer
    Peyrou, Marion
    Bourgoin, Lucie
    Foti, Michelangelo
    DIGESTIVE DISEASES, 2010, 28 (01) : 236 - 246
  • [43] Surgical Treatment of Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease
    Weiner, R. A.
    DIGESTIVE DISEASES, 2010, 28 (01) : 274 - 279
  • [44] An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia
    Hsu, Ching-Sheng
    Kao, Jia-Horng
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (08) : 759 - 772
  • [45] Hyperuricemia in non-alcoholic fatty liver disease
    Dogru, T.
    Genc, H.
    Tapan, S.
    Bagci, S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (08) : 1042 - 1043
  • [46] The epidemiology of non-alcoholic fatty liver disease
    Bellentani, Stefano
    LIVER INTERNATIONAL, 2017, 37 : 81 - 84
  • [47] Pathology of non-alcoholic fatty liver disease
    Bedossa, Pierre
    LIVER INTERNATIONAL, 2017, 37 : 85 - 89
  • [48] Non-alcoholic fatty liver disease and diabetes
    Reyes-Garcia, Rebeca
    Rozas-Moreno, Pedro
    Julio Llamoza-Torres, Camilo
    Mezquita-Raya, Pedro
    MEDICINA CLINICA, 2017, 148 (01): : 33 - 38
  • [49] Non-alcoholic fatty liver disease in children
    Chaturvedi, Kanupriya
    Vohra, Pankaj
    INDIAN PEDIATRICS, 2012, 49 (09) : 757 - 758
  • [50] Mitochondria in non-alcoholic fatty liver disease
    Prip-Buus, C.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2016, 46 : 53 - 53